Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS

Acta Neurologica Scandinavica

Volumn 109, Issue 5, 2004, Pages 337-341

  Pirttila T ^a   Vanhatalo, S ^b   Turpeinen, U ^b   Riikonen, R ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Insulin growth factor; Multiple sclerosis; Nitric oxide

Indexed keywords

NITRIC OXIDE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C;

ADULT; AGE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPSARRHYTHMIA; MALE; MULTIPLE SCLEROSIS; OPTIC NERVE ATROPHY; PROTEIN CEREBROSPINAL FLUID LEVEL; UPREGULATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NITRIC OXIDE; REFERENCE VALUES; SPINAL CORD; STATISTICS; UP-REGULATION;

EID: 2342614161     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2004.00223.x     Document Type: Article

References (37)

1. LIPTON SA, CHOI Y-B, SUCHER NJ, CHEN H-SV. Neuroprotective versus neurodestructive effects of NO-related species. BioFactors 1998;8:33-40.
2. BEAL MF, FERRANTE RJ, BROWNE SE, MATTHEWS RT, KOWALL NW, BROWN RH JR. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997;42:646-54.
3. MUNOZ-FERNANDEZ MA, FRESNO M. The role of tumour necrosis factor, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998;56:307-40.
4. MERRILL JE, IGNARRO LJ, SHERMAN MP, MELINEK J, LANE TE. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 1993;151:2132-41.
5. VAN DER VEEN RC, ROBERTS LJ. Contrasting roles for nitric oxide and peroxynitrite in the peroxidation of myelin lipids. J Neuroimmunol 1999;95:1-7.
6. LEIST M, NICOTERA P. Apoptosis, excitotoxicity, and neuropathology. Exp Cell Res 1998;239:183-201.
7. SPAGNOLI A, ROSENFELD RG. Insulin-like growth factor binding proteins. Curr Opin Endocrinol Diabet 1997;4: 1-9.
8. MOZELL RL, MCMORRIS FA. Insulin-like growth factor 1 stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res 1991; 30:382-90.
9. YE P, CARSON J, D'ERCOLE AJ. In vivo actions of insulin-like growth factor-1 (IGF-1) on brain myelination: studies of IGF-1 and IGF binding protein-1 (OGFBP-1) transgenic mice. J Neurosci 1995;15:7344-56.
10. MUNIYAPPA R, WALSH MF, RANGI JS et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci 1997;61:925-31.
11. TAGAMI M, YAMAGATA K, NARA Y et al. Insulin-like growth factor prevent apoptosis in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Lab Invest 1997;76:603-12.
12. HEVEL JM, MARLETTA MA. Nitric oxide synthase assays. Methods Enzymol 1994;233:250-8.
13. BRUNDIN L, MORCOS E, OLSSON T, WIKLUND NP, ANDERSSON M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 1999;6:585-90.
14. CROSS AH, MANNING PT, KEELING RM, SCHMIDT RE, MISKO TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 1998;88: 45-56.
15. GIOVANNONI G, HEALES SJR, LAND JM, THOMPSON EJ. The potential role of nitric oxide in multiple sclerosis. Mult Scler 1998;4:212-6.
16. -) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 1997;153:32-4.
17. SVENNlNGSSON A, PETERSSON AS, ANDERSEN O, HANSSON GK. Nitric oxide metabolites in CSF of patients with MS are related to clinical course. Neurology 1999;53:1880-2.
18. TREVOR D, MIKE S, ALASTAIR S. Cerebrospinal fluid nitric oxide metabolites and discrimination of bacterial meningitis from other causes of encephalopathy. Arch Dis Childhood 1997;76:290-1.
19. TSUKAHARA H, HARUTA T, HATA I, MAYUMI M. Nitric oxide in septic and aseptic meningitis in children. Scand J Clin Lab Invest 1998;58:73-80.
20. PELTOLA J, UKKONEN M, MOILANEN E, ELOVAARA I. Increased nitric oxide products in CSF in primary proressive MS may reflect brain atrophy. Neurology 2001;57:895-6.
21. RODRIGUEZ-SAINZ M, SANCHEZ-RAMON S, DE ANDRES C, RODRIGUEZ-MAHOU M, MUNOZ-FERNANDEZ M. Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis. Eur Cytokine Netw 2002;13:110-4
22. DE BUSTOS F, NAVARRO JA, DE ANDRES C et al. Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur Neurol 1999;41:44-7.
23. IKEDA M, SATO I, MATSUNAGA T et al. Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis, multiple sclerosis and Guillain-Barre syndrome. Int Med 1995;34:734-7.
24. WILCZAK N, SCHAAF M, BREDEWOLD R, STREEPLAND C, TEELKEN A, DE KEYSER J. Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis. Neurosci Lett 1998;257:168-70.
25. RIIKONEN R, SOMER M, TURPEINEN U. Low insulin-like growth factor (IGF-1) in the cerebrospinal fluid of children with the PEHO syndrome (progressive encephalopathy, hysarrhythmia and optic atrophy) and cerebellar degeneration. Epilepsia 1999;40:1642-8.
26. VANHATALO S, RIIKONEN R. Markedly elevated nitrate/nitrite levels in the cerebrospinal fluid of children with progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO syndrome). Epilepsia 2000;41:705-8.
27. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
28. SWASH M, LEIGH PN. Criteria for diagnosis of familial amyotrophic lateralis sclerosis. Neuromusc Disord 1992; 2:7-9.
29. DE GROOT CJA, RUULS SR, THEEUWES JWM, DUKSTRA CD, VAN DER VALK P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997;56:10-20.
30. GVERIC D, CUZNER ML, NEWCOMBE J. Insulin-like growth factors and binding proteins in multiple sclerosis plaques. Neuropathol Appl Neurobiol 1999;25:215-25.
31. GIOVANNONI G, HEALES SJR, SILVER NC et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci 1997;145:77-81.
32. TRAN EH, HARDIN-POUZET H, VERGE G, OWENS T. Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J Neuroimmunol 1997;74:121-9.
33. LEVENTHAL PS, RUSSELL JW, FELDMAN EL. IGFs and the nervous system. In: ROSENFELD RG, ROBERTS CT JR, eds. The IGF system. Molecular biology, physiology, and clinical applications. New York: Humana Press, 1999; 425-44.
34. TORRES-ALEMAN I, BARRIOS V, BERCIANO J. The peripheral insulin-like growth factor system in amyotrophic lateral sclerosis and in multiple sclerosis. Neurology 1998;50: 772-6.
35. LEWIS ME, NEFF NT, CONTRERAS PC et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993;124:73-88.
36. HANTAI D, AKAABOUNE M, LAGORD C et al. Beneficial effects of insulin-like growth factor I on wobbler mouse motoneuron disease. J Neurol Sci 1995;129(Suppl. 1):122-6.
37. HEINZE E, BOKER M, BLUM W et al. GH, IGF-1, IGFBP-3 and IGFBP-2 in cerebrospinal fluid of infants, during puberty and in adults. Exp Clin Endocrinol Diabetes 1998;106:197-202.